Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.


CSE:IMCC - Post by User

Comment by steveM45on Aug 27, 2020 11:36am
76 Views
Post# 31460537

RE:Info.

RE:Info.I like the cash position, no debt, long term sales contracts, margins and PS Ratio, which is high at around 23 but still far less than industry averages.

I don't like the increase in marketing costs and hope they are front-loaded and not required to rise in proportion to rev's next qtr.

Market didn't seem to notice today.  Hopefully Israeli legalization brings more attention to this one.  With a 225mil mkt cap this could be a grower.

Good Investing All!

Seppi2019 wrote:
As at June 30, 2020, the Company had a working capital surplus of $27,305, compared to working capital of $9,124 as at June 30, 2019. The increase in working capital of $18,181 was primarily attributable to the YWi^  hW_i[Z  \hec  j^[  <ecfWdoti  [gk_jo  \_dWdY_d]  and  exercise  of  warrants  and  broker  compensation options. As of June 30, 2020 the Company had an unaudited cash balance of $13,221 and no debt.

All amounts in the MD& A are expressed in Canadian Dollars ($) in thousands, unless otherwise noted.


<< Previous
Bullboard Posts
Next >>